Table 1.
Clinicopathological characteristics of primary breast cancer.
| Characteristics a | Study Groups | P-Value | ||
|---|---|---|---|---|
| CE-CT | PET/CT | |||
| Primary tumor size (mm) | 18 (3–65) | 20 (1–80) | 0.85 | |
| Bilateral cancer | 2 (5.9) | 5 (16.1) | 0.24 | |
| Histopathology | Ductal | 26 (76.5) | 23 (74.2) | 0.59 |
| Lobular | 5 (14.7) | 3 (9.7) | ||
| Adenocarcinoma | 3 (8.8) | 3 (9.7) | ||
| Unknown | 0 (0) | 2 (6.5) | ||
| Primary surgery (lumpectomy/mastectomy) | 23 (67.6) | 27 (87.1) | 0.06 | |
| Estrogen receptor status | Positive | 31 (91.2) | 25 (80.7) | 0.43 |
| Negative | 2 (5.9) | 3 (9.7) | ||
| Unknown | 1 (2.9) | 3 (9.7) | ||
| HER-2 status | Positive | 5 (14.7) | 6 (19.4) | 0.94 |
| Negative | 21 (61.8) | 18 (58.1) | ||
| Unknown | 8 (23.5) | 7 (22.6) | ||
| Tumor grade | Grade 1 | 6 (17.7) | 6 (19.4) | 0.98 |
| Grade 2 | 14 (41.2) | 11 (35.5) | ||
| Grade 3 | 7 (20.6) | 8 (25.8) | ||
| Unknown | 7 (20.6) | 6 (19.4) | ||
| Ki-67 proliferation (%) | 20 (1–80) | 50 (10–95) | 0.16 | |
| Lymph node involvement | None | 7 (20.6) | 6 (19.4) | 0.71 |
| Micro-metastasis | 4 (11.8) | 3 (9.7) | ||
| Macro-metastasis | 13 (38.2) | 16 (51.6) | ||
| Unknown | 10 (29.4) | 6 (19.4) | ||
| Treatment protocol | Neo-adjuvant treatment | 2 (5.88) | 8 (25.8) | 0.09 |
| Endocrine treatment | 23 (67.7) | 17 (54.8) | ||
| No treatment / unknown | 9 (26.5) | 6 (19.4) | ||
| Radiotherapy (breast/breast + axilla) | 20 (58.8) | 21 (67.7) | 0.31 | |
CE-CT: contrast-enhanced computed tomography; FDG-PET/CT: fluorodeoxyglucose positron emission tomography with integrated computed-tomography; HER-2: human epidermal growth factor receptor-2. a Data were shown as median (interquartile range) or frequency (percentage).